Beam Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -31.43%. Beam Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 2.54.
Beam Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -12.37%.
Beam Therapeutics ROE % Adjusted to Book Value Related Terms
Beam Therapeutics ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Beam Therapeutics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics ROE % Adjusted to Book Value Chart
MEX:BEAM vs DNLI, ORKA, DYN: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Beam Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -12.37% mean?
Beam Therapeutics (MEX:BEAM) has a ROE % Adjusted to Book Value of -12.37% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' ROE % Adjusted to Book Value too high?
Beam Therapeutics' current ROE % Adjusted to Book Value is -12.37%. Overall, Beam Therapeutics has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' ROE % Adjusted to Book Value compare to DNLI and ORKA?
Beam Therapeutics' ROE % Adjusted to Book Value of -12.37% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current ROE % Adjusted to Book Value is -12.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN528.66, compared to a current price of MXN628.46 — trading 18.9% above its estimated fair value. The current ROE % Adjusted to Book Value is -12.37%. Beam Therapeutics' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current ROE % Adjusted to Book Value is -12.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?
Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued.
The current stock price of MXN628.46 is trading 18.9% above its estimated GF Value™ of MXN528.66.
GuruFocus considers Beam Therapeutics to be Modestly Overvalued.
Key valuation signals for MEX:BEAM:
ROE % Adjusted to Book Value: -12.37%
GF Value™: MXN528.66 vs. price of MXN628.46 (18.9% above fair value)
No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
66GF Score
Get the complete analysis for MEX:BEAM
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BEAM has been successfully added to your 
